title: Promising effect of chemotherapy with bevacizumab for patients with pulmonary pleomorphic carcinoma: Two case reports and a literature review.
abstract: Pulmonary pleomorphic carcinoma (PPC) is a rare disease with a poor prognosis. Chemotherapy regimens used to date have not been effective against PPC; thus, a new treatment strategy is needed. Here, we report two patients with PPC who were effectively treated with a chemotherapy regimen including bevacizumab. Both patients received carboplatin/paclitaxel/bevacizumab and showed a partial response. As patients with PPC have been reported to show high expression of vascular endothelial growth factor (VEGF), the tumor specimens from the presented patients also showed high expression of VEGF. Therefore, a chemotherapy regimen including a VEGF inhibitor such as bevacizumab is a promising treatment for patients with PPC.
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan. Electronic address: ezm07452@nifty.ne.jp.
authors.forename: Tsuneyuki
authors.initials: T
authors.lastname: Oda
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan. Electronic address: Akimasa.Sekine@gmail.com.
authors.forename: Akimasa
authors.initials: A
authors.lastname: Sekine
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan. Electronic address: t-kato@kanagawa-junko.jp.
authors.forename: Terufumi
authors.initials: T
authors.lastname: Kato
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan. Electronic address: baba@kanagawa-junko.jp.
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Baba
authors.affiliation: Department of Pathology, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Electronic address: krascv@yahoo.co.jp.
authors.forename: Koji
authors.initials: K
authors.lastname: Okudela
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-higashi, Kanazawa-ku, Yokohama 236-0051, Japan. Electronic address: ogura@kanagawa-junko.jp.
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogura
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D017239:Paclitaxel / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel
keywords: bevacizumab,; chemotherapy,; pulmonary pleomorphic carcinoma,; vascular endothelial growth factor